Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers.
Sense Biodetection is a molecular diagnostics company .
T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.
Epitopea is a transatlantic cancer immunotherapeutics company.
BeyondMath develops an AI simulation platform for optimizing complex physical designs without supercomputers or physical prototypes.
Salience Labs provides photonic switch technology and optical networking solutions tailored for AI infrastructure.
Sortera Bio operates as a biotechnology company.
Mosaic Therapeutics is an oncology therapeutics company that develops targeted combination therapies for cancer patients.
TRIMTECH Therapeutics treats inflammatory and persistent CNS conditions by focusing on the elimination of harmful proteins.
Cambridge GaN Devices is a semiconductor company focused on developing GaN power devices aimed at creating greener electronics.
Forefront RF is a fabless semiconductor company.
Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers.
Riverlane develops software solutions to harness the power of quantum computers for practical applications.
Machine learning for automotive innovators
Phosphor AI provides personalized AI tutoring solutions for secondary education.
Complement Therapeutics operates as a preclinical stage company.
An AI and machine learning deployment, management and observability platform.
Targeting pathways that modify RNA to deliver novel cancer therapeutics
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated.
Unlikely AI is a talented group that is approaching artificial intelligence from a daring, fresh angle.
PetMedix is a pet therapeutics startup.
Exvastat is an innovative, preclinical-stage pharmaceutical company.
AudioTelligence delivers real-time audio processing technology for the enhancement of automatic speech recognition (ASR) systems.
PolyProx Therapeutics is a developer of a novel class of drug intended to provide new therapies for cancer treatment.
Cambridge Innovation Capital has invested in 52 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cambridge Innovation Capital's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 27 different industry categories.
Among tracked funding rounds, Complement Therapeutics received $78.7M in a Series A round. Cambridge Innovation Capital's total known invested capital is $1.2B.
Cambridge Innovation Capital's average investment size is $26.5M across its portfolio of 52 companies.
Recent Cambridge Innovation Capital portfolio additions include Nuclera, Sense Biodetection, T-Therapeutics, Epitopea, BeyondMath. These companies were founded in 2020 or later.